Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Anticevic

Showing results (151-160 of 181) with videos related to

Pageof 19
Sort By:
Biological Psychiatry|August 24, 2024
Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for PsychosisCharles H Schleifer, Sarah E Chang, Carolyn M Amir, et al.
Molecular Psychiatry|May 24, 2021
White matter changes in psychosis risk relate to development and are not impacted by the transition to psychosisMaria A Di Biase, Suheyla Cetin-Karayumak, Amanda E Lyall, et al.
Biological Psychiatry|September 6, 2021
Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA CohortNikolaos Koutsouleris, Michelle Worthington, Dominic B Dwyer, et al.
Schizophrenia (Heidelberg, Germany)|May 21, 2025
Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerationsDiana O Perkins, Clark D Jeffries, Scott R Clark, et al.
Schizophrenia Research|May 14, 2020
Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefitScott W Woods, Carrie E Bearden, Fred W Sabb, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical TrialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2023
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPSScott W Woods, Sophie Parker, Melissa J Kerr, et al.
Journal of Psychiatric Research|January 10, 2026
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Translational Psychiatry|March 18, 2021
White matter microstructure and its relation to clinical features of obsessive-compulsive disorder: findings from the ENIGMA OCD Working GroupFabrizio Piras, Federica Piras, Yoshinari Abe, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia ProgramNora Penzel, Pablo Polosecki, Jean Addington, et al.
Pageof 19

Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
Biological Psychiatry|August 24, 2024
Unique Functional Neuroimaging Signatures of Genetic Versus Clinical High Risk for PsychosisCharles H Schleifer, Sarah E Chang, Carolyn M Amir, et al.
Molecular Psychiatry|May 24, 2021
White matter changes in psychosis risk relate to development and are not impacted by the transition to psychosisMaria A Di Biase, Suheyla Cetin-Karayumak, Amanda E Lyall, et al.
Biological Psychiatry|September 6, 2021
Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA CohortNikolaos Koutsouleris, Michelle Worthington, Dominic B Dwyer, et al.
Schizophrenia (Heidelberg, Germany)|May 21, 2025
Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerationsDiana O Perkins, Clark D Jeffries, Scott R Clark, et al.
Schizophrenia Research|May 14, 2020
Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefitScott W Woods, Carrie E Bearden, Fred W Sabb, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical TrialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2023
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPSScott W Woods, Sophie Parker, Melissa J Kerr, et al.
Journal of Psychiatric Research|January 10, 2026
A translational neuroscience & computational evaluation of a D1R partial agonist for schizophrenia (TRANSCENDS): Rationale and study design of a brain-based clinical trialClara Fonteneau, Zailyn Tamayo, Ally Price, et al.
Translational Psychiatry|March 18, 2021
White matter microstructure and its relation to clinical features of obsessive-compulsive disorder: findings from the ENIGMA OCD Working GroupFabrizio Piras, Federica Piras, Yoshinari Abe, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia ProgramNora Penzel, Pablo Polosecki, Jean Addington, et al.
Pageof 19